All Ozempic (semaglutide) articles
-
NewsAstraZeneca seals obesity deal as Pfizer-Novo Nordisk battle for Metsera
After Wegovy and Zepbound's success, competition for the next potential weight loss blockbuster heats up.
-
NewsPfizer acquires Metsera and its GLP-1 candidates in new $4.9bn obesity play
The deal with the US biopharma adds a portfolio of clinical-stage incretin and amylin research programmes to its pipeline.
-
ArticlePotential blockbuster drugs to watch in 2025
Eleven drugs are poised to make waves in the pharmaceutical industry in 2025, according to the annual report.
-
NewsGLP-1 receptor agonists aid broader outcomes in kidney disease, major analysis finds
The analysis reveals multiple benefit in patients with type 2 diabetes and obesity with cardiovascular disease, or chronic kidney disease (CKD).
-
ArticleHarnessing the GLP-1R medicine wave
As a promising treatment for type 2 diabetes and obesity, based on key trial data, the market for glucagon-like peptide-1 receptor (GLP-1R) therapies looks set to generate major sales up to 2030.
-
NewsFrom biologics to small molecules – the shift in biopharma’s revenue growth
Biopharma companies that experienced strong revenue growth due to COVID-19 drug sales have been overtaken by companies that developed obesity drugs in 2023, GlobalData suggests.
-
Article2024 Pharmaceutical industry trends - discover the latest pharma quality and manufacturing trends
Some of the most sought-after human experiences are health and happiness. Although pharmaceutical companies cannot determine personal happiness, they are working to improve personal health outcomes that can tip the scale. The demand for personalised medicines, cell and gene therapies, hyperresponsive and patient-centric healthcare, real-world data fuelled by artificial intelligence ...